Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Wyszukujesz frazę ""Chemotherapy"" wg kryterium: Temat


Starter badań:

Tytuł:
The Addition of Hypomethylating Agents to Low-Intensity Induction Chemotherapy Does Not Improve Outcomes in Elderly Acute Myeloid Leukemia Patients: A Single-Center Retrospective Study.
Autorzy:
Liu D; Department of Hematology, Anhui Provincial Hospital, WanNan Medical College, Wenchang Xi Road No. 22, Wuhu 241002, China.
Wang X; Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei 230001, China.
Tong J; Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei 230001, China.
Zhou L; Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei 230001, China.
Chen E; Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei 230001, China.
Zhou Z; Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei 230001, China.
Xue L; Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei 230001, China.
Zhang X; Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei 230001, China.
Sun G; Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei 230001, China.
Zheng C; Department of Hematology, Anhui Provincial Hospital, WanNan Medical College, Wenchang Xi Road No. 22, Wuhu 241002, China.; Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Lujiang Road No. 17, Hefei 230001, China.
Pokaż więcej
Źródło:
Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2023 Jan 06; Vol. 59 (1). Date of Electronic Publication: 2023 Jan 06.
Typ publikacji:
Journal Article
MeSH Terms:
Induction Chemotherapy*
Leukemia, Myeloid, Acute*/drug therapy
Humans ; Aged ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Prognosis ; Remission Induction ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Tytuł:
Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.
Autorzy:
Gebremariam GT; School of Pharmacy, Addis Ababa University, Zambia Street, P.O. box: 1176, Addis Ababa, Ethiopia. .
Fentie AM; School of Pharmacy, Addis Ababa University, Zambia Street, P.O. box: 1176, Addis Ababa, Ethiopia.
Beyene K; Department of Pharmaceutical and Administrative Sciences, University of Health Sciences and Pharmacy in St. Louis, St. Louis, USA.
Sander B; Institute of Health Policy, Management, and Evaluation, University of Toronto, 155 College Street, Toronto, Ontario, M5T 3M6, Canada.; Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, 200 Elizabeth Street, Toronto, Ontario, M5G 2C4, Canada.; Institute for Clinical Evaluative Sciences, 2075 Bayview Ave, Toronto, Ontario, M4N 3M5, Canada.; Public Health Ontario, 480 University Ave, Toronto, Ontario, M5G 1V2, Canada.
Gebretekle GB; Institute of Health Policy, Management, and Evaluation, University of Toronto, 155 College Street, Toronto, Ontario, M5T 3M6, Canada.; Toronto Health Economics and Technology Assessment (THETA) Collaborative, University Health Network, 200 Elizabeth Street, Toronto, Ontario, M5G 2C4, Canada.; Centre for Vaccine-Preventable Diseases, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
Pokaż więcej
Źródło:
BMC health services research [BMC Health Serv Res] 2022 Dec 30; Vol. 22 (1), pp. 1600. Date of Electronic Publication: 2022 Dec 30.
Typ publikacji:
Systematic Review; Journal Article
MeSH Terms:
Chemotherapy-Induced Febrile Neutropenia*/drug therapy
Chemotherapy-Induced Febrile Neutropenia*/etiology
Chemotherapy-Induced Febrile Neutropenia*/prevention & control
Antineoplastic Agents*/adverse effects
Lymphoma*
Febrile Neutropenia*/chemically induced
Febrile Neutropenia*/prevention & control
Febrile Neutropenia*/drug therapy
Humans ; Filgrastim ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Cost-Benefit Analysis ; Polyethylene Glycols ; Recombinant Proteins ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Tytuł:
What is the Role of Induction Chemotherapy in the Treatment of Locally Advanced Sinonasal Squamous Cell Carcinoma?
Autorzy:
Abiri A; Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, California, USA.
St John MA; Department of Head and Neck Surgery, University of California, Los Angeles, Los Angeles, California, USA.
Kuan EC; Department of Otolaryngology-Head and Neck Surgery, University of California, Irvine, Orange, California, USA.; Department of Neurological Surgery, University of California, Irvine, Orange, California, USA.
Pokaż więcej
Źródło:
The Laryngoscope [Laryngoscope] 2023 Feb; Vol. 133 (2), pp. 214-215. Date of Electronic Publication: 2022 Nov 02.
Typ publikacji:
Journal Article
MeSH Terms:
Induction Chemotherapy*
Head and Neck Neoplasms*/drug therapy
Humans ; Squamous Cell Carcinoma of Head and Neck/drug therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cisplatin
Czasopismo naukowe
Tytuł:
ASO Visual Abstract: A Randomized Controlled Trial Investigating Perioperative Immunonutrition for Patients Undergoing Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).
Autorzy:
Tan GHC; Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore. .; Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Singapore General Hospital, Singapore, Singapore. .
Wong JSM; Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Singapore General Hospital, Singapore, Singapore.; Duke-NUS Medical School, SingHealth Duke-NUS Oncology Academic Clinical Program, Singapore, Singapore.; Duke-NUS Medical School, SingHealth Duke-NUS Surgery Academic Clinical Program, Singapore, Singapore.
Ong CJ; Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Singapore General Hospital, Singapore, Singapore.; Duke-NUS Medical School, SingHealth Duke-NUS Oncology Academic Clinical Program, Singapore, Singapore.; Duke-NUS Medical School, SingHealth Duke-NUS Surgery Academic Clinical Program, Singapore, Singapore.; Laboratory of Applied Human Genetics, Division of Medical Sciences, National Cancer Centre Singapore, Singapore, Singapore.; Institute of Molecular and Cell Biology, A*STAR Research Entities, Singapore, Singapore.
Ong WS; Division of Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, Singapore, Singapore.
Zhu HY; Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Singapore General Hospital, Singapore, Singapore.
Chia CS; Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Singapore General Hospital, Singapore, Singapore.; Duke-NUS Medical School, SingHealth Duke-NUS Oncology Academic Clinical Program, Singapore, Singapore.; Duke-NUS Medical School, SingHealth Duke-NUS Surgery Academic Clinical Program, Singapore, Singapore.
Teo MCC; Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, National Cancer Centre Singapore, Singapore, Singapore.; Department of Sarcoma, Peritoneal and Rare Tumours (SPRinT), Division of Surgery and Surgical Oncology, Singapore General Hospital, Singapore, Singapore.; Duke-NUS Medical School, SingHealth Duke-NUS Oncology Academic Clinical Program, Singapore, Singapore.; Duke-NUS Medical School, SingHealth Duke-NUS Surgery Academic Clinical Program, Singapore, Singapore.
Pokaż więcej
Źródło:
Annals of surgical oncology [Ann Surg Oncol] 2023 Feb; Vol. 30 (2), pp. 790-791.
Typ publikacji:
Randomized Controlled Trial; Journal Article
MeSH Terms:
Hyperthermic Intraperitoneal Chemotherapy*
Hyperthermia, Induced*
Humans ; Cytoreduction Surgical Procedures ; Immunonutrition Diet ; Combined Modality Therapy ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Survival Rate ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Re-induction therapy in patients with acute myeloid leukemia not in complete remission after the first course of treatment.
Autorzy:
Fu W; Department of Hematology, Institute of Hematology, Changhai Hospital, 168 Changhai Road, Shanghai, 200433, China.
Hu Y; Department of Obstetrics and Gynecology, Changhai Hospital, Shanghai, 200433, China.
Lu G; Department of Hematology, Institute of Hematology, Changhai Hospital, 168 Changhai Road, Shanghai, 200433, China.
Xu L; Department of Hematology, Institute of Hematology, Changhai Hospital, 168 Changhai Road, Shanghai, 200433, China.
Gao L; Department of Hematology, Institute of Hematology, Changhai Hospital, 168 Changhai Road, Shanghai, 200433, China.
Chen J; Department of Hematology, Institute of Hematology, Changhai Hospital, 168 Changhai Road, Shanghai, 200433, China.
Chen L; Department of Hematology, Institute of Hematology, Changhai Hospital, 168 Changhai Road, Shanghai, 200433, China.
Tang G; Department of Hematology, Institute of Hematology, Changhai Hospital, 168 Changhai Road, Shanghai, 200433, China.
Ni X; Department of Hematology, Institute of Hematology, Changhai Hospital, 168 Changhai Road, Shanghai, 200433, China. .
Yang J; Department of Hematology, Institute of Hematology, Changhai Hospital, 168 Changhai Road, Shanghai, 200433, China. .
Pokaż więcej
Źródło:
Annals of hematology [Ann Hematol] 2023 Feb; Vol. 102 (2), pp. 329-335. Date of Electronic Publication: 2023 Jan 12.
Typ publikacji:
Journal Article
MeSH Terms:
Induction Chemotherapy*
Leukemia, Myeloid, Acute*/drug therapy
Humans ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cytarabine ; Remission Induction ; Prognosis
Czasopismo naukowe
Tytuł:
Induction chemotherapy with sequential nimotuzumab plus concurrent chemoradiotherapy in advanced nasopharyngeal carcinoma: A retrospective real-world study.
Autorzy:
Jiang D; Department of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Cao J; Department of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Guo L; Department of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Chen Y; Department of Pathology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Yuan G; Department of Radiotherapy, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Huang J; Department of Head and Neck Oncology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, China.
Pokaż więcej
Źródło:
Medicine [Medicine (Baltimore)] 2023 Jan 27; Vol. 102 (4), pp. e32732.
Typ publikacji:
Journal Article
MeSH Terms:
Induction Chemotherapy*
Nasopharyngeal Neoplasms*/pathology
Humans ; Nasopharyngeal Carcinoma/drug therapy ; Retrospective Studies ; Cisplatin/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Neoplasm Staging ; Chemoradiotherapy/adverse effects ; Taxoids/therapeutic use
Czasopismo naukowe
Tytuł:
Gemcitabine Versus Docetaxel Plus Cisplatin as Induction Chemotherapy in Nasopharyngeal Carcinoma.
Autorzy:
Chen Q; National Clinical Research Center for Geriatric Disorders, Department of Geriatrics, Xiangya Hospital, Central South University, Changsha, China.
Li S; Department of Oncology, Xiangya Hospital, Central South University, Changsha, China.
Pokaż więcej
Źródło:
The Laryngoscope [Laryngoscope] 2022 Dec; Vol. 132 (12), pp. 2379-2387. Date of Electronic Publication: 2022 Mar 03.
Typ publikacji:
Journal Article
MeSH Terms:
Induction Chemotherapy*
Nasopharyngeal Neoplasms*/drug therapy
Nasopharyngeal Neoplasms*/pathology
Humans ; Nasopharyngeal Carcinoma/pathology ; Cisplatin ; Docetaxel/therapeutic use ; Retrospective Studies ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemoradiotherapy ; Gemcitabine
Czasopismo naukowe
Tytuł:
Consolidation chemotherapy in AML: Are we playing with a full deck of cards?
Autorzy:
Stone RM; Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, D2053, Boston, MA, 02215, USA. Electronic address: richard_.
Pokaż więcej
Źródło:
Best practice & research. Clinical haematology [Best Pract Res Clin Haematol] 2022 Dec; Vol. 35 (4), pp. 101408. Date of Electronic Publication: 2022 Oct 29.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Consolidation Chemotherapy*
Leukemia, Myeloid, Acute*/drug therapy
Leukemia, Myeloid, Acute*/genetics
Humans ; Aged ; Cytarabine/therapeutic use ; Remission Induction ; Stem Cell Transplantation ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
Czasopismo naukowe
Tytuł:
Consolidation Chemotherapy Rather than Induction Chemotherapy Can Prolong the Survival Rate of Inoperable Esophageal Cancer Patients Who Received Concurrent Chemoradiotherapy.
Autorzy:
Xia X; Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China.
Wu M; Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China.; The First School of Clinical Medicine, Nanjing Medical University, Nanjing 210029, China.
Gao Q; Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China.; The First School of Clinical Medicine, Nanjing Medical University, Nanjing 210029, China.
Sun X; Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China.
Ge X; Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing 210029, China.
Pokaż więcej
Źródło:
Current oncology (Toronto, Ont.) [Curr Oncol] 2022 Sep 02; Vol. 29 (9), pp. 6342-6349. Date of Electronic Publication: 2022 Sep 02.
Typ publikacji:
Journal Article
MeSH Terms:
Consolidation Chemotherapy*
Esophageal Neoplasms*/drug therapy
Chemoradiotherapy ; Humans ; Induction Chemotherapy ; Retrospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł:
Real-world evaluation of supportive care using an electronic health record text-mining tool: G-CSF use in breast cancer patients.
Autorzy:
van Laar SA; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333ZA, Leiden, The Netherlands.
Gombert-Handoko KB; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333ZA, Leiden, The Netherlands.
Wassenaar S; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333ZA, Leiden, The Netherlands.
Kroep JR; Department of Medical Oncology, Leiden University Medical Center, Leiden, The Netherlands.
Guchelaar HJ; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333ZA, Leiden, The Netherlands.
Zwaveling J; Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Albinusdreef 2, 2333ZA, Leiden, The Netherlands. .
Pokaż więcej
Źródło:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2022 Nov; Vol. 30 (11), pp. 9181-9189. Date of Electronic Publication: 2022 Aug 31.
Typ publikacji:
Journal Article
MeSH Terms:
Breast Neoplasms*/epidemiology
Chemotherapy-Induced Febrile Neutropenia*/prevention & control
Febrile Neutropenia*/drug therapy
Humans ; Female ; Granulocyte Colony-Stimulating Factor ; Retrospective Studies ; Electronic Health Records ; Data Mining ; Antineoplastic Combined Chemotherapy Protocols/adverse effects
Czasopismo naukowe
Tytuł:
Optimal induction chemotherapy regimen for locoregionally advanced nasopharyngeal carcinoma: an update Bayesian network meta-analysis.
Autorzy:
Wu Q; Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Li S; Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Liu J; Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China.
Zhong Y; Department of Radiation and Medical Oncology, Hubei Key Laboratory of Tumor Biological Behaviors, Hubei Cancer Clinical Study Center, Zhongnan Hospital of Wuhan University, Wuhan, 430071, China. .
Pokaż więcej
Źródło:
European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery [Eur Arch Otorhinolaryngol] 2022 Nov; Vol. 279 (11), pp. 5057-5069. Date of Electronic Publication: 2022 Jun 29.
Typ publikacji:
Journal Article; Meta-Analysis; Review; Systematic Review
MeSH Terms:
Induction Chemotherapy*
Nasopharyngeal Neoplasms*/drug therapy
Nasopharyngeal Neoplasms*/pathology
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Bayes Theorem ; Chemoradiotherapy ; Cisplatin/therapeutic use ; Humans ; Nasopharyngeal Carcinoma/drug therapy ; Nasopharyngeal Carcinoma/pathology ; Network Meta-Analysis
Czasopismo naukowe
Tytuł:
The Prognostic Utility of Lymphocyte-Based Measures and Ratios in Chemotherapy-Induced Febrile Neutropenia Patients following Granulocyte Colony-Stimulating Factor Therapy.
Autorzy:
Halalsheh OM; Division of Urology, Department of General Surgery and Urology, Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan.
Al Zu'bi YO; Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan.
Al Sharie AH; Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan.
Wafai FH; Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan.
Alabdallah N; Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan.
AlSeidi J; Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan.
Hussein AA; Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan.
Daoud MN; Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan.
Malkawi AA; Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan.
Alomari AO; Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan.
Alshari O; Division of Oncology, Department of Internal Medicine, Faculty of Medicine, Jordan University of Science & Technology, Irbid 22110, Jordan.
Pokaż więcej
Źródło:
Medicina (Kaunas, Lithuania) [Medicina (Kaunas)] 2022 Oct 24; Vol. 58 (11). Date of Electronic Publication: 2022 Oct 24.
Typ publikacji:
Journal Article
MeSH Terms:
Chemotherapy-Induced Febrile Neutropenia*
Humans ; Prognosis ; Retrospective Studies ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Lymphocytes ; Neutrophils ; Antineoplastic Combined Chemotherapy Protocols
Czasopismo naukowe
Tytuł:
Evaluating the safety and effectiveness of PegaGen (pegfilgrastim) for the prevention of chemotherapy-induced febrile neutropenia: a post-marketing surveillance study.
Autorzy:
Jenabian A; Department of Medical Oncology and Hematology, Booali Hospital, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran. .
Ehsanpour A; Thalassemia and Hemoglobinopathy Research Center, Research Institute of Health, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Mortazavizadeh SMR; Department of Internal, Faculty of Medicine, Islamic Azad University, Yazd, Iran.
Raafat J; Mehrad Hospital, Tehran, Iran.
Razavi M; Department of Oncology and Hematology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Khosravi A; Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Seifi S; Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Salimi B; Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Anjidani N; Medical Department, Orchid Pharmed Company, Tehran, Iran.
Kafi H; Medical Department, Orchid Pharmed Company, Tehran, Iran.
Pokaż więcej
Źródło:
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer [Support Care Cancer] 2022 Oct; Vol. 30 (10), pp. 8151-8158. Date of Electronic Publication: 2022 Jul 06.
Typ publikacji:
Journal Article; Multicenter Study
MeSH Terms:
Antineoplastic Agents*/adverse effects
Breast Neoplasms*/drug therapy
Chemotherapy-Induced Febrile Neutropenia*/drug therapy
Chemotherapy-Induced Febrile Neutropenia*/etiology
Chemotherapy-Induced Febrile Neutropenia*/prevention & control
Febrile Neutropenia*/chemically induced
Febrile Neutropenia*/drug therapy
Febrile Neutropenia*/prevention & control
Anti-Bacterial Agents/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Female ; Filgrastim/therapeutic use ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Humans ; Polyethylene Glycols/adverse effects ; Product Surveillance, Postmarketing ; Prospective Studies ; Recombinant Proteins/therapeutic use
Czasopismo naukowe
Tytuł:
Induction Chemotherapy and Chemoradiotherapy Combined to ASA vs. Placebo for High-Risk Rectal Cancer: Results of a Randomized Trial.
Autorzy:
Ominelli J; Division of Clinical Research, Instituto Nacional de Câncer (INCA), Rio de Janeiro (RJ), Brazil. Electronic address: .
Araujo ROC; Department of Abdomino-Pelvic Surgery, Instituto Nacional de Câncer (INCA), Rio de Janeiro (RJ), Brazil.
Valadão M; Department of Abdomino-Pelvic Surgery, Instituto Nacional de Câncer (INCA), Rio de Janeiro (RJ), Brazil.
Padoan MLA; Division of Clinical Research, Instituto Nacional de Câncer (INCA), Rio de Janeiro (RJ), Brazil.
Lopes Dos Santos VM; Division of Clinical Research, Instituto Nacional de Câncer (INCA), Rio de Janeiro (RJ), Brazil.
Dutra JG; Division of Clinical Research, Instituto Nacional de Câncer (INCA), Rio de Janeiro (RJ), Brazil.
Torres CC; Department of Radiology, Instituto Nacional de Câncer (INCA), Rio de Janeiro (RJ), Brazil.
Barbosa MA; Department of Radiology, Instituto Nacional de Câncer (INCA), Rio de Janeiro (RJ), Brazil.
Guimarães R; Department of Radiotherapy, Instituto Nacional de Câncer (INCA), Rio de Janeiro (RJ), Brazil.
Carvalho JCC; Department of Radiotherapy, Instituto Nacional de Câncer (INCA), Rio de Janeiro (RJ), Brazil.
Ferreira MA; Department of Endoscopy, Instituto Nacional de Câncer (INCA), Rio de Janeiro (RJ), Brazil.
de Oliveira IM; Department of Pathology, Instituto Nacional de Câncer (INCA), Rio de Janeiro (RJ), Brazil.
Small I; Division of Clinical Research, Instituto Nacional de Câncer (INCA), Rio de Janeiro (RJ), Brazil.
de Melo AC; Division of Clinical Research, Instituto Nacional de Câncer (INCA), Rio de Janeiro (RJ), Brazil.
Araujo LH; Division of Clinical Research, Instituto Nacional de Câncer (INCA), Rio de Janeiro (RJ), Brazil.
Pokaż więcej
Źródło:
Clinical colorectal cancer [Clin Colorectal Cancer] 2022 Sep; Vol. 21 (3), pp. e196-e204. Date of Electronic Publication: 2022 May 13.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial
MeSH Terms:
Induction Chemotherapy*/methods
Rectal Neoplasms*/pathology
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemoradiotherapy/methods ; Double-Blind Method ; Humans ; Neoadjuvant Therapy/methods ; Neoplasm Staging ; Treatment Outcome
Czasopismo naukowe
Tytuł:
Serum CA-125 and renal impairment in patients undergoing hyperthermic intraperitoneal chemotherapy.
Autorzy:
Bernal-Bello D; Department of Internal Medicine, Hospital Universitario de Fuenlabrada, Madrid, Spain. Electronic address: .
Guerra-Pérez I; Department of Medical Specialities and Public Health, Universidad Rey Juan Carlos, Madrid, Spain.
Alegre-Zahonero L; Department of Medical Specialities and Public Health, Universidad Rey Juan Carlos, Madrid, Spain; Department of Nephrology, Hospital Universitario de Fuenlabrada, Madrid, Spain.
Pokaż więcej
Źródło:
Biomedical journal [Biomed J] 2022 Oct; Vol. 45 (5), pp. 847-848. Date of Electronic Publication: 2021 Dec 11.
Typ publikacji:
Letter; Comment
MeSH Terms:
Hyperthermic Intraperitoneal Chemotherapy*
Cisplatin*
Humans ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Survival Rate
Opinia redakcyjna
Tytuł:
Two-drug versus three-drug induction chemotherapy in pediatric acute myeloid leukemia: a randomized controlled trial.
Autorzy:
Radhakrishnan V; Department of Medical Oncology, Cancer Institute (WIA) Adyar, Chennai, India. .
Bakhshi S; Department of Medical Oncology, Dr. BRA IRCH, All India Institute of Medical Sciences, New Delhi, India.
Kayal S; Department of Medical Oncology, JIPMER, Puducherry, India.
Thampy C; Department of Medical Oncology, Cancer Institute (WIA) Adyar, Chennai, India.
Batra A; Department of Medical Oncology, Cancer Institute (WIA) Adyar, Chennai, India.
Shenoy PK; Department of Medical Oncology, Cancer Institute (WIA) Adyar, Chennai, India.
Kumar H; Department of Medical Oncology, Cancer Institute (WIA) Adyar, Chennai, India.
Rajaraman S; Department of Biostatistics, Cancer Institute (WIA) Adyar, Chennai, India.
Chaudhary S; Department of Medical Oncology, Dr. BRA IRCH, All India Institute of Medical Sciences, New Delhi, India.
Bisht R; Department of Medical Oncology, Dr. BRA IRCH, All India Institute of Medical Sciences, New Delhi, India.
Dubashi B; Department of Medical Oncology, JIPMER, Puducherry, India.
Ganesan TS; Department of Medical Oncology, Cancer Institute (WIA) Adyar, Chennai, India.
Pokaż więcej
Źródło:
Blood cancer journal [Blood Cancer J] 2022 Sep 06; Vol. 12 (9), pp. 131. Date of Electronic Publication: 2022 Sep 06.
Typ publikacji:
Journal Article; Randomized Controlled Trial
MeSH Terms:
Induction Chemotherapy*
Leukemia, Myeloid, Acute*
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Child ; Cytarabine/therapeutic use ; Daunorubicin/adverse effects ; Female ; Humans ; Male ; Remission Induction
Czasopismo naukowe
Tytuł:
MRI-based radiomics to compare the survival benefit of induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy plus adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A multicenter study.
Autorzy:
Shen H; Department of Radiology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, China.
Yin J; Department of Medical Imaging, Affiliated Cancer Hospital & Institute of Guangzhou Medical University, China.
Niu R; Department of Radiology, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Lian Y; Department of Radiology, The First Affiliated Hospital of Zhengzhou University, China.
Huang Y; Department of Hematology, Chongqing General Hospital, University of the Chinese Academy of Sciences, China.
Tu C; Department of Radiology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, China.
Liu D; Department of Radiology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, China.
Wang X; Department of Radiology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, China.
Lan X; Department of Radiology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, China.
Yuan X; Department of Radiology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, China.
Zhang J; Department of Radiology, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, China. Electronic address: zhangjq_.
Pokaż więcej
Źródło:
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2022 Jun; Vol. 171, pp. 107-113. Date of Electronic Publication: 2022 Apr 21.
Typ publikacji:
Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
MeSH Terms:
Induction Chemotherapy*/methods
Nasopharyngeal Neoplasms*/drug therapy
Nasopharyngeal Neoplasms*/therapy
Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Chemoradiotherapy/methods ; Chemotherapy, Adjuvant/methods ; Humans ; Magnetic Resonance Imaging ; Nasopharyngeal Carcinoma/drug therapy ; Nasopharyngeal Carcinoma/therapy ; Neoplasm Recurrence, Local/drug therapy
Czasopismo naukowe
Tytuł:
Impact of Relative Dose Intensity of FOLFOX Adjuvant Chemotherapy on Risk of Death Among Stage III Colon Cancer Patients.
Autorzy:
Zhou M; Epidemiology Program, School of Public Health and Louisiana Tumor Registry, Louisiana State University Health Sciences Center, New Orleans, LA.
Thompson TD; Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA.
Lin HY; Biostatistics Program, School of Public Health, Louisiana State University Health Sciences Center, New Orleans, LA.
Chen VW; Epidemiology Program, School of Public Health and Louisiana Tumor Registry, Louisiana State University Health Sciences Center, New Orleans, LA.
Karlitz JJ; Division of Gastroenterology, School of Medicine, Tulane University; Gastroenterologist Southeast Louisiana Veteran Health Care System, New Orleans, LA.
Fontham ETH; Epidemiology Program, School of Public Health and Louisiana Tumor Registry, Louisiana State University Health Sciences Center, New Orleans, LA.
Theall KP; Department of Global Community Health and Behavioral Sciences, School of Public Health and Tropical Medicine, Tulane University, New Orleans, LA.
Zhang L; Department of Public Health Sciences, Clemson University, Clemson, SC.
Hsieh MC; Epidemiology Program, School of Public Health and Louisiana Tumor Registry, Louisiana State University Health Sciences Center, New Orleans, LA.
Pollack LA; Division of Cancer Prevention and Control, National Center for Chronic Disease Prevention and Health Promotion, Centers for Disease Control and Prevention, Atlanta, GA.
Wu XC; Epidemiology Program, School of Public Health and Louisiana Tumor Registry, Louisiana State University Health Sciences Center, New Orleans, LA. Electronic address: .
Pokaż więcej
Źródło:
Clinical colorectal cancer [Clin Colorectal Cancer] 2022 Jun; Vol. 21 (2), pp. e62-e75. Date of Electronic Publication: 2021 Oct 01.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, P.H.S.
MeSH Terms:
Antineoplastic Combined Chemotherapy Protocols*/adverse effects
Colonic Neoplasms*/pathology
Chemotherapy, Adjuvant ; Humans ; Neoplasm Staging ; Proportional Hazards Models ; Retrospective Studies
Czasopismo naukowe
Tytuł:
Bortezomib-cyclophosphamide-dexamethasone induction/consolidation and bortezomib maintenance for transplant-eligible newly diagnosed multiple myeloma: phase 2 multicenter trial.
Autorzy:
Muranushi H; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kanda J; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Kobayashi M; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.; Department of Hematology, Japan Baptist Hospital, Kyoto, Japan.
Maeda T; Department of Haematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
Kitano T; Department of Hematology, Medical Research Institute Kitano Hospital, Osaka, Japan.
Tsuji M; Department of Hematology and Immunology, Otsu Red Cross Hospital, Otsu, Japan.
Ueda Y; Department of Haematology/Oncology, Kurashiki Central Hospital, Kurashiki, Japan.
Ishikawa T; Department of Hematology, Kobe City Hospital Organization Kobe City Medical Center General Hospital, Kobe, Japan.
Nohgawa M; Department of Hematology, Japanese Red Cross Society Wakayama Medical Center, Wakayama, Japan.
Watanabe M; Department of Hematology, Hyogo Prefectural Amagasaki General Medical Center, Amagasaki, Japan.
Imada K; Department of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Moriguchi T; Department of Internal Medicine, Kyoto-Katsura Hospital, Kyoto, Japan.
Itoh M; Department of Hematology, Kyoto City Hospital, Kyoto, Japan.
Ohno H; Department of Hematology, Tenri Hospital, Tenri, Japan.
Yonezawa A; Department of Hematology, Kokura Memorial Hospital, Kitakyushu, Japan.
Hirata H; Department of Hematology, Kansai Electric Power Hospital, Osaka, Japan.
Arima N; Department of Hematology, Medical Research Institute Kitano Hospital, Osaka, Japan.
Asagoe K; Department of Hematology and Oncology, Shiga General Hospital, Moriyama, Japan.
Anzai N; Department of Hematology and Oncology, Takatsuki Red Cross Hospital, Takatsuki, Japan.
Nagata K; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Yasuno S; Clinical Research Support Center, The Jikei University School of Medicine, Tokyo, Japan.
Kuwabara Y; Cancer Control Center, Osaka International Cancer Institute, Osaka, Japan.
Kitao H; Department of Data Science, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan.
Kim I; Department of Data Science, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan.
Kawagishi K; Department of Data Science, Institute for Advancement of Clinical and Translational Science, Kyoto University Hospital, Kyoto, Japan.
Ueshima K; Center for Accessing Early Promising Treatment, Kyoto University Hospital, Kyoto, Japan.
Tominari S; Department of Health Informatics, Kyoto University School of Public Health, Kyoto, Japan.
Nakayama T; Department of Health Informatics, Kyoto University School of Public Health, Kyoto, Japan.
Yamashita K; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Takaori-Kondo A; Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Pokaż więcej
Źródło:
Hematology (Amsterdam, Netherlands) [Hematology] 2022 Dec; Vol. 27 (1), pp. 239-248.
Typ publikacji:
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms:
Induction Chemotherapy*
Multiple Myeloma*/mortality
Multiple Myeloma*/therapy
Stem Cell Transplantation*
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Adult ; Aged ; Autografts ; Bortezomib/administration & dosage ; Cyclophosphamide/administration & dosage ; Dexamethasone/administration & dosage ; Disease-Free Survival ; Female ; Humans ; Japan/epidemiology ; Male ; Middle Aged ; Prospective Studies ; Survival Rate
Czasopismo naukowe
Tytuł:
Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed?
Autorzy:
Boccia R; Center for Cancer and Blood Disorders, Bethesda, MD, USA.
Glaspy J; UCLA School of Medicine, Los Angeles, CA, USA.
Crawford J; Duke Cancer Institute, Duke University School of Medicine, Durham, NC, USA.
Aapro M; Cancer Centre, Clinique de Genolier, Genolier, Switzerland.
Pokaż więcej
Źródło:
The oncologist [Oncologist] 2022 Aug 05; Vol. 27 (8), pp. 625-636.
Typ publikacji:
Journal Article; Review; Research Support, Non-U.S. Gov't
MeSH Terms:
Antineoplastic Agents*/therapeutic use
Biosimilar Pharmaceuticals*/therapeutic use
Chemotherapy-Induced Febrile Neutropenia*/epidemiology
Chemotherapy-Induced Febrile Neutropenia*/etiology
Neoplasms*/drug therapy
COVID-19 Drug Treatment*
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols ; Child ; Granulocyte Colony-Stimulating Factor/therapeutic use ; Humans ; Pandemics
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies

Prześlij opinię

Twoje opinie są dla nas bardzo ważne i mogą być niezwykle pomocne w pokazaniu nam, gdzie możemy dokonać ulepszeń. Bylibyśmy bardzo wdzięczni za poświęcenie kilku chwil na wypełnienie krótkiego formularza.

Formularz